Monopar Therapeutics (MNPR) Cash from Operations (2017 - 2025)

Monopar Therapeutics has reported Cash from Operations for 9 years, with the latest figure at 3370072.0 in Q4 2025.

• Quarterly Cash from Operations fell 68.64% year-over-year to 3370072.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 12201291.0 (down 90.52% YoY) and the FY2025 annual result came in at 12201291.0, down 90.52% from the prior year.
• Cash from Operations retreated to 3370072.0 in Q4 2025 per MNPR's latest filing, from 2090532.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 1073500.0 in Q3 2024 and troughed at 5663316.0 in Q1 2025.
• A 5-year average of 2050484.15 and a median of 1940564.5 in 2021 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2024 and 2025: Cash from Operations soared 44.66% in 2024, then plunged 242.11% in 2025.
• Over 5 years, Cash from Operations stood at 2031905.0 in 2021, then jumped by 35.93% to 1301806.0 in 2022, then decreased by 18.75% to 1545899.0 in 2023, then fell by 29.27% to 1998418.0 in 2024, then tumbled by 68.64% to 3370072.0 in 2025.
• According to Business Quant data, Cash from Operations over the past three periods registered 3370072.0, 2090532.0, and 1077371.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.